<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03082950</url>
  </required_header>
  <id_info>
    <org_study_id>HL-15-220</org_study_id>
    <nct_id>NCT03082950</nct_id>
  </id_info>
  <brief_title>HPV Infections, Cancer of the Vulva and Therapeutical Success</brief_title>
  <official_title>Influence of Hpv Infections on Therapeutical Outcome of Patients Suffering From Vulvar Cancer and Ist Preinvasive Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Luebeck</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>EUROIMMUN Medizinische Labordiagnostika AG</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Luebeck</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      HPV infections may be responsible for different types of cancer in females. Primary Goal of
      the study was to identify the prevalence of an hpv affiliation in retrospective-prospective
      analysed cohort of patients who suffer from vulvar cancer and their preinvasive lesions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HPV infections may be responsible for different types of cancer in females. Primary Goal of
      the study was to identify the prevalence of an hpv affiliation in retrospective-prospective
      analysed cohort of patients who suffer from vulvar cancer and their preinvasive lesions.

      After having retrospectively identified patients with vulvar cancer incl. their preinvasive
      lesions in the clinical registry the hpv status of the samples is prospectively analyzed
      using a new multiplex pcr Array. Two Groups are build: patients with hpv associated vulvar
      cancer and patients with non-hpv associated vulvar cancer.

      Then, the rate of patients who respond to radiotherapy within the Groups is analyzed by
      building Kaplan meier plots according to the patients survival and recurrence rate.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2015</start_date>
  <completion_date type="Actual">May 2018</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>prevalence of hpv infections among pations suffering from vulvar cancer and preinvasive lesions</measure>
    <time_frame>15yrs</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>disease free survival among the groups</measure>
    <time_frame>15yrs</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">110</enrollment>
  <condition>HPV</condition>
  <condition>Human Papilloma Virus</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>human papilloma Virus (hpv) associated vulvar cancer incl. preinvasive lesions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>non-human papilloma Virus (hpv) associated vulvar cancer incl. preinvasive lesions</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>polymerase chain reaction</intervention_name>
    <description>PCR is performed with all patients. The result (hpv positive or negative) will define the patiens Group Affiliation.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>EUROARRAY</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tumor tissue samples are analyzed according to their hpv status
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        pts. who suffer from vulvar cancer and their preinvasive lesions who were treated in
        luebeck University medical Center over a 15 year period
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pts. who suffer from vulvar cancer and their preinvasive lesions

          -  positive informed consent

          -  complete set of data

          -  Treatment in luebeck university

        Exclusion Criteria:

          -  opposite of above
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>female the illness only affiliates females</gender_description>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Beyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Westpfalz-Klinikum</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Luebeck University, Department for obstetrics and gynecology</name>
      <address>
        <city>Luebeck</city>
        <state>Schleswig Holstein</state>
        <zip>D-23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Massad LS, Jeronimo J, Katki HA, Schiffman M; National Institutes of Health/American Society for Colposcopy and Cervical Pathology Research Group. The accuracy of colposcopic grading for detection of high-grade cervical intraepithelial neoplasia. J Low Genit Tract Dis. 2009 Jul;13(3):137-44. doi: 10.1097/LGT.0b013e31819308d4.</citation>
    <PMID>19550210</PMID>
  </reference>
  <reference>
    <citation>Sri T, Merideth MA, Pulanic TK, Childs R, Stratton P. Human papillomavirus reactivation following treatment of genital graft-versus-host disease. Transpl Infect Dis. 2013 Aug;15(4):E148-51. doi: 10.1111/tid.12098. Epub 2013 May 28.</citation>
    <PMID>23710698</PMID>
  </reference>
  <reference>
    <citation>Nocon M, Mittendorf T, Roll S, Greiner W, Willich SN, von der Schulenburg JM. Review on the medical and health economic evidence for an inclusion of colposcopy in primary screening programs for cervical cancer. GMS Health Technol Assess. 2007 Aug 10;3:Doc07.</citation>
    <PMID>21289941</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2017</study_first_submitted>
  <study_first_submitted_qc>March 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2017</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Luebeck</investigator_affiliation>
    <investigator_full_name>Daniel Alexander Beyer</investigator_full_name>
    <investigator_title>University of Luebeck</investigator_title>
  </responsible_party>
  <keyword>hpv prevalence</keyword>
  <keyword>recurrence rate</keyword>
  <keyword>survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Papilloma</mesh_term>
    <mesh_term>Papillomavirus Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

